| Literature DB >> 33065603 |
Xiao-Lin Su1,2, Jiang-Wei Wang3, Hui Che4, Chang-Fu Wang5, Hai Jiang1, Xia Lei1, Wan Zhao1, Hai-Xue Kuang1, Qiu-Hong Wang5.
Abstract
ABSTRACT: Lung cancer is a malignant tumor characterized by a rapid proliferation rate, less survivability, high mortality, and metastatic potential. This review focuses on updated research about the clinical application of traditional Chinese medicine (TCM) as an adjuvant therapy to lung cancer treatment and the mechanisms of TCM effect on lung cancer in vitro and in vivo. We summarized the recent 5 years of different research progress on clinical applications and antitumor mechanisms of TCM in the treatment of lung cancer. As a potent adjuvant therapy, TCM could enhance conventional treatments (chemotherapy, radiation therapy, and epidermal growth factor receptors [EGFRs] tyrosine kinase inhibitors [TKIs]) effects as well as provide synergistic effects, enhance chemotherapy drugs chemosensitivity, reverse drug resistance, reduce adverse reactions and toxicity, relieve patients' pain and improve quality of life (QOL). After treating with TCM, lung cancer cells will induce apoptosis and/or autophagy, suppress metastasis, impact immune reaction, and therapeutic effect of EGFR-TKIs. Therefore, TCM is a promisingly potent adjuvant therapy in the treatment of lung cancer and its multiple mechanisms are worthy of an in-depth study.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33065603 PMCID: PMC7752681 DOI: 10.1097/CM9.0000000000001141
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Summary of clinical application of TCM in treatment of lung cancer
| Author | Year | TCM Type | Clinical Application | Methods | (sample quantity) Lung Cancer Types | Results |
| Jiao L, Dong C, Liu J, | 2017 | Formula I (including qi and warming yang granules); Formula II (nourishing yin and promoting the secretion of body fluid granules); Formula III was a combination of formula I and formula II; Formula IV (detoxifying and resolving masses granules). | Combine platinum-based chemotherapy. | RCT | (314) IB, II or IIIA NSCLC patients | Reduce side-effects (4.02% to 0.57%), relief of symptoms ((hemoglobin reduction (11.9% |
| Wang J, Li G, Yu L, | 2016 | Aidi injection (composed by the extracts of Cantharis,Astragalus, senticosus Eleutherococcus and Ginseng). | Combine platinum-based chemotherapy. | Systematic review and meta-analysis of RCTs. | (4081) Stage IIIB/IV NSCLC patients | Increase relative benefit of DCR and ORR. Improve 1-, 2-, 3-year survival rates, QOL and reduce severe toxicities by 36%. |
| Xiao Z, Wang C, Sun Y, | 2018 | Aidi injection (composed by the extracts of Cantharis,Astragalus, senticosus Eleutherococcus and Ginseng). | Combine platinum-based chemotherapy | Systematic review and meta-analysis of RCTs | (1390) NSCLC patients | Improve the clinical efficacy and restore the cellular immunity damaged by platinum-based chemotherapy. |
| Wang X, Liu Z, Sui X, | 2019 | Elemene injection (extracted from the traditional Chinese medicinal plant Curcuma aromatica Salisb) | Combine platinum-based chemotherapy. | Systematic review and meta-analysis of RCTs. | (1410) Stage III/IV NSCLC patients | Improve DCR, ORR, 1- and 2-year survival rates, QOL, CD4+T cell counts, CD4+/CD8+ratio and reduce severe toxicities. |
| Wang Q, Jiao L, Wang S, | 2020 | Basic Herbs (Xia Ku Cao, Sheng Nan Xing, She Liu Gu, etc); Yiqi formula (Huang Qi, Dang Shen, Bai Zhu, etc); Yangyin formula (Bei Sha Shen, Tian Dong, Bai He, etc). | Combine chemotherapy after radical surgery. | Multicenter, randomized, double-blind, placebo-controlled trial. | (233) IB∼IIIA stage lung adenocarcinoma | Prolong the DFS time (from 37.1 to 51.5 months) especially in the early stage, reduces the chemotherapy-related toxic and side effects. |
| Zhao X, Dai X, Wang S, | 2018 | Huangqi, Dangshen, Baizhu, Fuling, Chenpi, Xingren, etc. | Combine chemotherapy after radical surgery. | RCT | (67) Stage II-IIIA NSCLC | Reduce the rate of tumor recurrence, metastasis and prolong DFS. |
| Wang S, Lian X, Sun M, | 2016 | Kushen injection | Combine radiotherapy. | Systematic review | (1558) NSCLC | Improve the clinical effect and reduce the incidence of adverse events. |
| Wang LJ, Lu JZ, Cai BN, | 2017 | Zhuye Shigao Granule | Combine radiotherapy. | RCT | (62) Lung cancer patients | Decrease the incidence and grade of ARIE, delay the time of occurrence, reduce duration and alleviate the damage of ARIE. |
| Liu J, Lin HS, Hou W, | 2017 | Zhenqi Fuzheng Granules, Jianpi Yishen Granules, Shengxue Pill. | Combine chemotherapy and radiotherapy. | Multicenter, prospective, cohort study. | (474) Stage III-IV NSCLC | Prolong survival (median survival from 13.13 months to 16.60 months) and improve the QOL patients with NSCLC, reduce adverse effects of radio-and chemotherapy. |
| Tang M, Wang S, Zhao B, | 2019 | Er Chen Tang (Pinellia ternata (15 g), Dried tangerine peel (10 g), Poria cocos (20 g), Licorice (10 g) etc. plus San Ren Tang(Phragmites stem (30 g), Wax gourd seed (20 g), Peach seed (15 g), Coix seed (30 g), Honeysuckle (10 g) etc. | Combine EGFR-TKIs. | RCT | (153) Advanced-stage NSCLC patients harboring EGFR mutations | Prolong-progression-free survival (improve Median PFS 8.8 months to 13 months) and enhanced therapeutic effect in NSCLC patients harboring EGFR mutations, decrease adverse effects. |
| Liu ZL, Zhu WR, Zhou WC, | 2014 | TCM | Combine EGFR-TKIs. | Systematic review and meta-analysis | (1159) NSCLC | Increase efficacy and reduce toxicity. |
| He W, Cheng M[ | (1391) Advanced NSCLC | |||||
| Han Y, Wang H, Xu W, | 2015 | Radix astragali, dry radix ginseng, Adenophora tetraphylla, Dioscorea opposita Thunb.etc. | Maintenance therapy | RCT | (106) Advanced NSCLC | Improve the QOL of advanced NSCLC patients. |
| Jiang Y, Liu LS, Shen LP, | 2016 | Cinobufacini injection, shenghuangqi, Radix Codonopsis, Pericarpium Citri Reticulatae.etc | Maintenance therapy | RCT | (64) Advanced NSCLC | Improve patients’ QOL and higher 1-year survival rate; serum concentration of sCTLA-4 may be one of the mechanisms of TCM maintenance treatment of NSCLC. |
ARIE: Acute radiation-induced esophagitis; DCR: Disease control rate; DFS: Disease-free survival; EGFR: Epidermal growth factor receptors; EGFR-TKIs: Epidermal growth factor receptors tyrosine kinase inhibitors; NSCLC: Non-small cell lung cancer; ORR: Objective response rate; QOL: Quality of life; RCT: Randomized controlled trial; sCTLA-4: Serum Cytotoxic T lymphocyte associated antigen-4; TCM: Traditional Chinese Medicine.
Figure 1Mechanisms of TCM in the treatment of lung cancer. EGFR: Epidermal growth factor receptor; TCM: Traditional Chinese medicine; TKI: Tyrosine kinase inhibitors.